U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory T-Cell Prolymphocytic Leukemia

MedGen UID:
1672901
•Concept ID:
C4763795
•
Neoplastic Process

Definition

T-cell prolymphocytic leukemia that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory T-Cell Prolymphocytic Leukemia

Professional guidelines

PubMed

Advances and Perspectives in the Treatment of T-PLL.
Braun T, von Jan J, Wahnschaffe L, Herling M
Curr Hematol Malig Rep 2020 Apr;15(2):113-124. doi: 10.1007/s11899-020-00566-5. PMID: 32034661Free PMC Article
The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol 2006 Apr;33(2 Suppl 5):S44-52. doi: 10.1053/j.seminoncol.2006.01.029. PMID: 16720203
Management of chronic lymphocytic leukaemia.
Kalil N, Cheson BD
Drugs Aging 2000 Jan;16(1):9-27. doi: 10.2165/00002512-200016010-00002. PMID: 10733261

Recent clinical studies

Etiology

A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM
Cancer 2023 Feb 15;129(4):580-589. Epub 2022 Nov 29 doi: 10.1002/cncr.34570. PMID: 36448227
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
Hu Z, Medeiros LJ, Fang L, Sun Y, Tang Z, Tang G, Sun T, Quesada AE, Hu S, Wang SA, Pei L, Lu X
Am J Hematol 2017 May;92(5):441-447. Epub 2017 Feb 27 doi: 10.1002/ajh.24679. PMID: 28194886
Monoclonal antibody therapies in leukemias.
Tallman MS
Semin Hematol 2002 Oct;39(4 Suppl 3):12-9. doi: 10.1053/shem.2002.36923. PMID: 12447847
Management of chronic lymphocytic leukaemia.
Kalil N, Cheson BD
Drugs Aging 2000 Jan;16(1):9-27. doi: 10.2165/00002512-200016010-00002. PMID: 10733261
T-small lymphocyte disorders.
Bartlett NL, Longo DL
Semin Hematol 1999 Apr;36(2):164-70. PMID: 10319385

Diagnosis

Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.
Smith VM, Lomas O, Constantine D, Palmer L, Schuh AH, Bruce D, Gonchar O, Macip S, Jayne S, Dyer MJS, Eyre TA
Blood Adv 2020 Feb 11;4(3):525-529. doi: 10.1182/bloodadvances.2019000917. PMID: 32040552Free PMC Article
Advances and Perspectives in the Treatment of T-PLL.
Braun T, von Jan J, Wahnschaffe L, Herling M
Curr Hematol Malig Rep 2020 Apr;15(2):113-124. doi: 10.1007/s11899-020-00566-5. PMID: 32034661Free PMC Article
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB
Blood 2017 Dec 7;130(23):2499-2503. Epub 2017 Sep 27 doi: 10.1182/blood-2017-05-785683. PMID: 28972014
Management of chronic lymphocytic leukaemia.
Kalil N, Cheson BD
Drugs Aging 2000 Jan;16(1):9-27. doi: 10.2165/00002512-200016010-00002. PMID: 10733261
T gamma lymphocytosis and T cell chronic leukemias.
Berliner N
Hematol Oncol Clin North Am 1990 Apr;4(2):473-87. PMID: 2182603

Therapy

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste E, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng S, Morschhauser F, Staber PB, Davids MS
Blood 2021 Jun 24;137(25):3495-3506. doi: 10.1182/blood.2020007303. PMID: 33598678
Advances and Perspectives in the Treatment of T-PLL.
Braun T, von Jan J, Wahnschaffe L, Herling M
Curr Hematol Malig Rep 2020 Apr;15(2):113-124. doi: 10.1007/s11899-020-00566-5. PMID: 32034661Free PMC Article
Alemtuzumab.
Frampton JE, Wagstaff AJ
Drugs 2003;63(12):1229-43; discussion 1245-6. doi: 10.2165/00003495-200363120-00003. PMID: 12790693
Monoclonal antibody therapies in leukemias.
Tallman MS
Semin Hematol 2002 Oct;39(4 Suppl 3):12-9. doi: 10.1053/shem.2002.36923. PMID: 12447847
T-small cell disorders.
Westin EH, Longo DL
Curr Treat Options Oncol 2001 Jun;2(3):225-35. doi: 10.1007/s11864-001-0036-2. PMID: 12057122

Prognosis

Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia.
Braun T, Stachelscheid J, Bley N, Oberbeck S, Otte M, Müller TA, Wahnschaffe L, Glaß M, Ommer K, Franitza M, Gathof B, Altmüller J, Hallek M, Auguin D, Hüttelmaier S, Schrader A, Herling M
Cancer Res 2022 May 3;82(9):1818-1831. doi: 10.1158/0008-5472.CAN-21-1908. PMID: 35259248
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
Hu Z, Medeiros LJ, Fang L, Sun Y, Tang Z, Tang G, Sun T, Quesada AE, Hu S, Wang SA, Pei L, Lu X
Am J Hematol 2017 May;92(5):441-447. Epub 2017 Feb 27 doi: 10.1002/ajh.24679. PMID: 28194886
Alemtuzumab.
Frampton JE, Wagstaff AJ
Drugs 2003;63(12):1229-43; discussion 1245-6. doi: 10.2165/00003495-200363120-00003. PMID: 12790693
T-small cell disorders.
Westin EH, Longo DL
Curr Treat Options Oncol 2001 Jun;2(3):225-35. doi: 10.1007/s11864-001-0036-2. PMID: 12057122
True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases.
Hoyer JD, Ross CW, Li CY, Witzig TE, Gascoyne RD, Dewald GW, Hanson CA
Blood 1995 Aug 1;86(3):1163-9. PMID: 7620169

Clinical prediction guides

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste E, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng S, Morschhauser F, Staber PB, Davids MS
Blood 2021 Jun 24;137(25):3495-3506. doi: 10.1182/blood.2020007303. PMID: 33598678
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
Hu Z, Medeiros LJ, Fang L, Sun Y, Tang Z, Tang G, Sun T, Quesada AE, Hu S, Wang SA, Pei L, Lu X
Am J Hematol 2017 May;92(5):441-447. Epub 2017 Feb 27 doi: 10.1002/ajh.24679. PMID: 28194886
Alemtuzumab.
Frampton JE, Wagstaff AJ
Drugs 2003;63(12):1229-43; discussion 1245-6. doi: 10.2165/00003495-200363120-00003. PMID: 12790693
Management of chronic lymphocytic leukaemia.
Kalil N, Cheson BD
Drugs Aging 2000 Jan;16(1):9-27. doi: 10.2165/00002512-200016010-00002. PMID: 10733261
True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases.
Hoyer JD, Ross CW, Li CY, Witzig TE, Gascoyne RD, Dewald GW, Hanson CA
Blood 1995 Aug 1;86(3):1163-9. PMID: 7620169

Recent systematic reviews

Advances and Perspectives in the Treatment of T-PLL.
Braun T, von Jan J, Wahnschaffe L, Herling M
Curr Hematol Malig Rep 2020 Apr;15(2):113-124. doi: 10.1007/s11899-020-00566-5. PMID: 32034661Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...